Obermatt
See Similar Stocks →

Ionis Pharmaceuticals

NSQ:IONS · US4622221004
BiotechnologyLarge

360

9
Profit price88
Owner Earnings Yield1
Dividend Yield1
Price/Sales40
EV / Gross Profit4
Price/Book100
Return on Capital54
Cash Return on Capital30
Return on Equity15
EBIT Margin25
Gross Profitability30
Accruals25
Owner Earnings Margin41
Sales growth31
Profit growth4
Reinvestment25
Price momentum77
Debt load16
Refinancing85
Debt Payback1
Liquidity44
Analyst ratings26
Opinion Changes83
Price Target Upside47
Market mood46
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Ionis Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded1989
Employees1,317
Websiteionis.com
ISINUS4622221004
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Health Care
Themes
GeneticsNephrologyCentral Nervous SystemGenetic DisorderChronic DiseasesInfectious DiseasesNeurologyCardiovascularHepatologyBiotechnologyHealth CareScience and Engineering

Description

Ionis Pharmaceuticals, Inc. is a pioneer in RNA-targeted medicines, with a deep understanding of disease biology and industry-leading drug discovery technology. In the last year, the company delivered on its strategy to create accelerating value for…

Analysis

Middle-of-the-road

Ionis Pharmaceuticals, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is stretched. The company scores 6/20 on our value-creation score: not creating value.

What to watch: The financial cushion is thinner than comfortable. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
32
2026

All-time high

32

Jun 2026

All-time low

4

Mar 2026

Average rank

18

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
40
—
—
—
Price/Earnings
87
—
—
—
Price/Book
100
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
86
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Ionis Pharmaceuticals with its peers
Biogen Idec
NSQ:BIIB
82
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
PTC Therapeutics
NSQ:PTCT
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Vertex Pharmaceuticals
NSQ:VRTX
63
CountryUSA
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Alpha Cognition
NAQ:ACOG
23
CountryCanada
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Larimar Therapeutics
NMQ:LRMR
26
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Alnylam Pharmaceuticals
NSQ:ALNY
79
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →